The global burden of liver disease: the major impact of China
- PMID: 25164003
- PMCID: PMC4867229
- DOI: 10.1002/hep.27406
The global burden of liver disease: the major impact of China
Abstract
Liver disease is a major cause of illness and death worldwide. In China alone, liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]), nonalcoholic fatty liver disease, and alcoholic liver disease, affect approximately 300 million people. The establishment of the Expanded Program on Immunization in 1992 has resulted in a substantial decline in the number of newly HBV-infected patients; however, the number of patients with alcoholic and nonalcoholic fatty liver diseases is rising at an alarming rate. Liver cancer, one of the most deadly cancers, is the second-most common cancer in China. Approximately 383,000 people die from liver cancer every year in China, which accounts for 51% of the deaths from liver cancer worldwide. Over the past 10 years, China has made some significant efforts to shed its "leader in liver diseases" title by investing large amounts of money in funding research, vaccines, and drug development for liver diseases and by recruiting many Western-trained hepatologists and scientists. Over the last two decades, hepatologists and scientists in China have made significant improvements in liver disease prevention, diagnosis, management, and therapy. They have been very active in liver disease research, as shown by the dramatic increase in the number of publications in Hepatology. Nevertheless, many challenges remain that must be tackled collaboratively. In this review, we discuss the epidemiology and characteristics of liver diseases and liver-related research in China.
© 2014 by the American Association for the Study of Liver Diseases.
Figures
Comment in
-
Reply: To PMID 25164003.Hepatology. 2015 Nov;62(5):1640-1. doi: 10.1002/hep.27768. Epub 2015 Apr 8. Hepatology. 2015. PMID: 25722010 No abstract available.
-
Liver disease in China: A long way to go.Hepatology. 2015 Nov;62(5):1640. doi: 10.1002/hep.27769. Epub 2015 Mar 25. Hepatology. 2015. PMID: 25722082 No abstract available.
-
Reply.Hepatology. 2016 Jan;63(1):348. doi: 10.1002/hep.27879. Epub 2015 Jun 19. Hepatology. 2016. PMID: 25953045 No abstract available.
-
Contribution of nonignorable environmental factor to impairing liver disease mortality reduction target in China.Hepatology. 2016 Jan;63(1):347-8. doi: 10.1002/hep.27882. Epub 2015 Jun 19. Hepatology. 2016. PMID: 25953408 No abstract available.
Similar articles
-
Global liver disease burdens and research trends: Analysis from a Chinese perspective.J Hepatol. 2019 Jul;71(1):212-221. doi: 10.1016/j.jhep.2019.03.004. Epub 2019 Mar 12. J Hepatol. 2019. PMID: 30871980 Review.
-
China's efforts to shed its title of "Leader in liver disease".Drug Discov Ther. 2007 Oct;1(2):84-5. Drug Discov Ther. 2007. PMID: 22504391
-
The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.Vaccine. 2013 Dec 27;31 Suppl 9:J15-20. doi: 10.1016/j.vaccine.2013.03.045. Vaccine. 2013. PMID: 24331015 Review.
-
Hepatology after Hepatitis C.Dig Dis. 2016;34(5):603-6. doi: 10.1159/000445276. Epub 2016 Jun 22. Dig Dis. 2016. PMID: 27332966
-
Tuberculosis.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
Cited by
-
Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B.Front Immunol. 2022 Sep 20;13:1024333. doi: 10.3389/fimmu.2022.1024333. eCollection 2022. Front Immunol. 2022. PMID: 36203581 Free PMC article.
-
Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.J Clin Lab Anal. 2023 Dec;37(23-24):e24990. doi: 10.1002/jcla.24990. Epub 2023 Dec 8. J Clin Lab Anal. 2023. PMID: 38063322 Free PMC article.
-
Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases.Dis Markers. 2020 Jul 21;2020:2471252. doi: 10.1155/2020/2471252. eCollection 2020. Dis Markers. 2020. PMID: 32774512 Free PMC article. Review.
-
Novel Copper(II) Complex with a 4-Acylpyrazolone Derivative and Coligand Induce Apoptosis in Liver Cancer Cells.ACS Med Chem Lett. 2021 Feb 26;12(3):467-476. doi: 10.1021/acsmedchemlett.0c00680. eCollection 2021 Mar 11. ACS Med Chem Lett. 2021. PMID: 33738074 Free PMC article.
-
The effectiveness of web-based interventions on non-alcoholic fatty liver disease (NAFLD) in obese children: A study protocol for a randomized controlled trial.Front Public Health. 2022 Oct 20;10:930901. doi: 10.3389/fpubh.2022.930901. eCollection 2022. Front Public Health. 2022. PMID: 36339187 Free PMC article.
References
-
- Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004;127:S303–S309. - PubMed
-
- Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):7–10. - PubMed
-
- Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59:160–168. - PubMed
-
- Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):11–17. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous